HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.